Tactile Systems Technology (NASDAQ:TCMD) Upgraded at StockNews.com

StockNews.com upgraded shares of Tactile Systems Technology (NASDAQ:TCMD) from a buy rating to a strong-buy rating in a research report released on Friday morning.

Separately, B. Riley cut shares of Tactile Systems Technology from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $23.00 to $18.00 in a research note on Wednesday, February 19th.

Tactile Systems Technology Trading Down 2.9 %

NASDAQ TCMD opened at $13.29 on Friday. Tactile Systems Technology has a 12 month low of $11.12 and a 12 month high of $21.10. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.36 and a quick ratio of 3.80. The company has a market capitalization of $313.44 million, a price-to-earnings ratio of 18.99 and a beta of 1.24. The company’s fifty day moving average price is $15.89 and its two-hundred day moving average price is $15.82.

Tactile Systems Technology (NASDAQ:TCMD) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.09. The company had revenue of $85.59 million for the quarter, compared to the consensus estimate of $85.39 million. Tactile Systems Technology had a net margin of 5.79% and a return on equity of 9.37%. As a group, research analysts predict that Tactile Systems Technology will post 0.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Daniel L. Reuvers sold 10,938 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $14.55, for a total value of $159,147.90. Following the completion of the transaction, the director now owns 242,942 shares in the company, valued at approximately $3,534,806.10. This represents a 4.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Elaine M. Birkemeyer sold 3,778 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $14.70, for a total transaction of $55,536.60. Following the completion of the transaction, the chief financial officer now owns 104,098 shares of the company’s stock, valued at approximately $1,530,240.60. This represents a 3.50 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 19,546 shares of company stock valued at $285,444. Company insiders own 0.96% of the company’s stock.

Institutional Investors Weigh In On Tactile Systems Technology

A number of hedge funds have recently added to or reduced their stakes in the stock. Jones Financial Companies Lllp acquired a new stake in shares of Tactile Systems Technology in the 4th quarter valued at approximately $39,000. Virtus Fund Advisers LLC grew its stake in shares of Tactile Systems Technology by 142.0% in the fourth quarter. Virtus Fund Advisers LLC now owns 4,199 shares of the company’s stock valued at $72,000 after buying an additional 2,464 shares in the last quarter. Quarry LP bought a new position in shares of Tactile Systems Technology in the fourth quarter valued at $81,000. 1620 Investment Advisors Inc. bought a new position in shares of Tactile Systems Technology in the fourth quarter valued at $97,000. Finally, Legal & General Group Plc boosted its position in Tactile Systems Technology by 33.2% during the fourth quarter. Legal & General Group Plc now owns 6,257 shares of the company’s stock worth $107,000 after purchasing an additional 1,558 shares during the period. Institutional investors own 83.43% of the company’s stock.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.